| Characteristic | No. of patients (%),n = 50 |
| Age (years) | |
| <61 | 18 (36) |
| 61–65 | 15 (30) |
| >65 | 17 (34) |
| Race | |
| African-American | 8 (16) |
| Caucasian | 42 (84) |
| Preoperative PSA level (ng/ml) | |
| <4 | 21 (42) |
| 4–10 | 26 (52) |
| >10 | 3 (6) |
| Pathological stage* | |
| pT2a | 10 (20) |
| pT2b | 5 (10) |
| pT2c | 35 (70) |
| Total tumour volume (cm3) | |
| <0.3 | 33 (66) |
| 0.3 to <0.5 | 17 (34) |
| Gleason score | |
| 4 | 1 (2) |
| 5 | 9 (18) |
| 6 | 38 (76) |
| 3+4 | 2 (4) |
| 4+3 | 0 (0) |
| WHO tumour differentiation | |
| Well | 36 (72) |
| Moderate | 12 (24) |
| Poor | 2 (4) |
| Benign glands in the surgical margin | |
| Positive | 19 (38) |
| Negative | 31 (62) |
| Multifocality (number of tumours) | |
| Single | 8 (16) |
| Multifocal | 42 (84) |
*1992 tumour, node, metastases (TNM) staging system.
PSA, prostate specific antigen; WHO, World Health Organization.